SCHEMBL7798261

SCHEMBL7798261

COc1ccc(Cc2cccc(N)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
CYP2D6 P10635 1/20 0.53
ATM Q13315 1/20 0.53
BACE1 P56817 2/20 0.52
LTA4H P09960 2/20 0.50
SLC6A4 P31645 1/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
APP P05067 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 1/20 0.45
MPO P05164 2/20 0.45
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
IDO1 P14902 1/20 0.42
AGXT P21549 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9391669 0.84 BACE1 (0.64) BACE1LTA4HTLR8TLR7IDO1
SCHEMBL28203653 0.81 LTA4H (0.52) ALDH1A1CYP2D6ATMLTA4HSLC6A4
SCHEMBL9391599 0.80 LTA4H (0.50) ALDH1A1CYP2D6ATMLTA4HSLC6A4
SCHEMBL9391608 0.80 LTA4H (0.46) ALDH1A1CYP2D6ATMLTA4HSLC6A4
SCHEMBL28040110 0.79 ALDH1A1 (0.51) ALDH1A1CYP2D6ATMLTA4HSLC6A4
SCHEMBL29758354 0.78 BACE1 (0.50) ALDH1A1BACE1APPTLR8
SCHEMBL1402167 0.78 BACE1 (0.50) ALDH1A1BACE1APPTLR8
SCHEMBL9395340 0.77 KCNH3 (0.47) BACE1HPGDAPPMPORAB9A
SCHEMBL7796022 0.77 ESR1 (0.46) ALDH1A1BACE1APPIDO1
SCHEMBL28043569 0.77 HSP90AB1 (0.54) ALDH1A1BACE1APPPOLBMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010034445-A1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION 2001-10-25 US disclosed
EP-0895475-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2000-08-23 EP disclosed
EP-0895475-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-10 EP disclosed
WO-1997024122-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed
WO-1994026715-A1 AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1994-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034445-A1 Vitronectin receptor antagonists ADGRF1, GPR174, CALCRL ALDH1A1 2598/4885CYP2D6 2676/4885ATM 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.